Universal Health Services (UHS)
(Delayed Data from NYSE)
$189.34 USD
-0.13 (-0.07%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $189.22 -0.12 (-0.06%) 7:04 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$189.34 USD
-0.13 (-0.07%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $189.22 -0.12 (-0.06%) 7:04 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Philips' (PHG) New Innovation to Enhance Cardiovascular Imaging
by Zacks Equity Research
Philips' (PHG) latest X11-4t Mini 3D TEE transducer is likely to have an edge over the traditional 3D TEE in terms of catering to a broader range of patients and improved overall comfort.
LabCorp (LH) Unveils Test for Preeclampsia in Pregnant Women
by Zacks Equity Research
LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.
Why Universal Health Services (UHS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Universal Health Services (UHS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.
Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow
by Zacks Equity Research
Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.
Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.
Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.
Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.
Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook
by Zacks Equity Research
Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.
Charles River (CRL) Launches Animal-Free Endotoxin Test
by Zacks Equity Research
Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.
ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries
by Zacks Equity Research
ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.
Here's Why Universal Health Services (UHS) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment
by Zacks Equity Research
Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.
Bruker (BRKR) to Advance in Lab Automation With New Buyout
by Zacks Equity Research
This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."
AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment
by Zacks Equity Research
AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.
BD (BDX) Collaborates With Hamilton to Benefit Researchers
by Zacks Equity Research
Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.
Why Universal Health Services (UHS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?
by Zacks Equity Research
Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.
Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform
by Zacks Equity Research
Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.
Fast-paced Momentum Stock Universal Health Services (UHS) Is Still Trading at a Bargain
by Zacks Equity Research
Universal Health Services (UHS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Dexcom (DXCM) Set to Solidify Its Business Throughout EMEA
by Zacks Equity Research
Dexcom (DXCM), opening a new manufacturing facility in the West of Ireland, is expected to boost production of rtCGM sensors and create employment.
McKesson (MCK) Set to Sell Canadian Rexall Pharmacy Group
by Zacks Equity Research
McKesson (MCK) is seeking buyers for the Canadian Rexall Pharmacy Group. The business is currently amid its second round of offers, with no set deadline for submissions.